

Product Information

Interleukin-6 Receptor Soluble Fragment human

recombinant, expressed in Sf 21 cells

I5771

Description

A soluble form of the Interleukin-6 receptor (IL-6R) was initially identified in the urine of healthy adult humans¹, in culture supernatants from HTLV-I positive T cell lines² and in the serum of HIV-sero positive blood donors.² These soluble receptors may develop as a result of alternate splicing of the mRNA or as a result of proteolytic cleavage and release of the membrane-bound form of the receptor. Recombinant Interleukin-6 Receptor Soluble Fragment human was produced by cloning the cDNA of the IL6R and introducing a stop codon into the cDNA sequence immediately preceding the transmembrane domain. This was followed by infection of Sf 21 insect cells with recombinant baculovirus encoding the sequence for the truncated receptor. The IL-6 soluble receptor is 339 amino acid residues in length.³ It may serve to transport IL-6, protecting IL-6 from proteolysis. Alternatively, the IL6 soluble receptor may act as an inhibitory agent to localize the activity of IL-6 or to bind IL-6 that is not bound to cell surface receptors. The bioactivity of IL-6 increases after binding to the soluble IL-6 receptor.

Reagent

Lyophilized from a 0.2 µm filtered solution of phosphate buffered saline, pH 7.4. containing 1.25 mg bovine serum albumin.

Precautions and Disclaimer

This product is for R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage

Prior to reconstitution, store at -20 °C for no more than 6 months. After reconstitution, store at 2-8 °C for a maximum of one month. For extended storage, freeze in working aliquots at -70 °C or -20 °C. Repeated freezing and thawing is not recommended.

Reconstitution and Use

Reconstitute the contents of the vial using 0.2 µm-filtered phosphate buffered saline containing 0.1% HSA or BSA to a concentration of not less than 5 µg/mL.

Product Profile

The biological activity is measured by its ability to increase the IL-6 induced inhibition of mouse M1 myeloid leukemia cells.⁴ The ED₅₀ is defined as the effective concentration of soluble receptor that elicits a 50% increase in IL-6 activity in a cell based bioassay.

Molecular Weight: 38 kDa

Purity: ≥ 97% (SDS-PAGE)

ED₅₀: 1-10 ng/mL

Endotoxin: ≤ 0.1 ng/µg IL-6 sR

References

1. Novick, D., et al., J. Exp. Med., 170, 1409 (1989).
2. Honda, M., et al., J. Immunol., 148, 2175 (1992).
3. Yamasaki, et al., Science, 241, 825 (1988).
4. Saito, T., J. Immunol., 147, 168 (1991).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

15771 Rev 03/22

MERCK